TY - JOUR
T1 - Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma
AU - Fuji, S.
AU - Fujiwara, H.
AU - Nakano, N.
AU - Wake, A.
AU - Inoue, Y.
AU - Fukuda, T.
AU - Hidaka, M.
AU - Moriuchi, Y.
AU - Miyamoto, T.
AU - Uike, N.
AU - Taguchi, J.
AU - Eto, T.
AU - Tomoyose, T.
AU - Kondo, T.
AU - Yamanoha, A.
AU - Ichinohe, T.
AU - Atsuta, Y.
AU - Utsunomiya, A.
N1 - Funding Information:
This work was supported by grants from the Japanese Ministry of Health, Labour and Welfare. We thank the medical, nursing, data-processing, laboratory and clinical staff at the participating centers for their important contributions to this study and their dedicated care of the patients.
Publisher Copyright:
© 2016 Macmillan Publishers Limited All rights reserved.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, <100 days, n=72; late transplant group, ≥100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3% vs 31.2%). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.
AB - Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, <100 days, n=72; late transplant group, ≥100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3% vs 31.2%). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.
UR - http://www.scopus.com/inward/record.url?scp=84956924452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956924452&partnerID=8YFLogxK
U2 - 10.1038/bmt.2015.265
DO - 10.1038/bmt.2015.265
M3 - Article
C2 - 26524263
AN - SCOPUS:84956924452
VL - 51
SP - 205
EP - 211
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 2
ER -